omniture
诚益生物

Latest News

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases

Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive...

2023-11-09 15:05 1348

Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

– Proceeds to support the development of Eccogene's clinical-stage metabolic pipeline including ECC...

2023-06-12 08:00 2377

Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004

BOSTON and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Ad...

2022-11-03 13:11 1935

Eccogene Announces US IND Approval for THRβ agonist ECC4703

SHANGHAI, Aug. 1, 2022 /PRNewswire/ -- Eccogene announced that the U.S. Food and Drug Administratio...

2022-08-01 15:00 1528

Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia

SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company ...

2021-07-28 17:13 1923

Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board

SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company...

2021-06-17 19:49 2168